- Home
- GLO vs ATAI Comparison
GLO vs ATAI Comparison
Compare GLO & ATAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GLO | ATAI |
|---|---|---|
| Founded | N/A | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 242.9M | 1.3B |
| IPO Year | 2006 | 2025 |
Fundamental Metrics
Financial Performance| Metric | GLO | ATAI |
|---|---|---|
| Price | $5.84 | $4.55 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $15.88 |
| AVG Volume (30 Days) | 103.9K | ★ 6.3M |
| Earning Date | 01-01-0001 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $4,089,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 1227.60 |
| 52 Week Low | $4.84 | $1.29 |
| 52 Week High | $6.09 | $6.73 |
Technical Indicators
Market Signals| Indicator | GLO | ATAI |
|---|---|---|
| Relative Strength Index (RSI) | 56.35 | 62.74 |
| Support Level | $5.57 | $3.41 |
| Resistance Level | $5.89 | $4.68 |
| Average True Range (ATR) | 0.07 | 0.31 |
| MACD | 0.01 | 0.10 |
| Stochastic Oscillator | 79.24 | 51.93 |
Price Performance
Historical ComparisonAbout GLO Clough Global Opportunities Fund
Clough Global Opportunities Fund is a closed-end management investment company based in the United States. Its investment objective is to provide a high level of total return by investing in equity securities of companies of any market capitalization and equity-related securities, including equity swaps and call options, as well as fixed-income securities, including both corporate and sovereign debt, in both U.S. and non-U.S. markets.
About ATAI ATAI Life Sciences N.V.
AtaiBeckley Inc is a clinical-stage biopharmaceutical company on a mission to transform patient outcomes by developing effective, rapid-acting, and convenient mental health treatments. AtaiBeckley's pipeline of novel therapies includes BPL-003 (mebufotenin benzoate nasal spray) for treatment-resistant depression (TRD), VLS-01 (DMT buccal film) for TRD and EMP-01 ((R)-MDMA HCI) for social anxiety disorder, which are in Phase 2 clinical development.